A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable

Roman Rouzier; Philippe Morice; Anne Floquet; Frédéric Selle; Eric Lambaudie; Virginie Fourchotte; Christophe Pomel; Raffaele Fauvet; Pierre Emmanuel Colombo; Elsa Kalbacher; Philippe Follana; Sandrine Martin; Anne Lesoin; Fabrice Lecuru; Patricia Pautier; Frederic Guyon; Paul H. Cottu; Florence Joly; Youssef Ghazi; Elisabeth Chereau

doi:10.1200/jco.2014.32.15_suppl.tps5614

Retour

A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable

Article de revue

Avec comité de lecture

A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable

Roman Rouzier, Philippe Morice, Anne Floquet, Frédéric Selle, Eric Lambaudie, Virginie Fourchotte, Christophe Pomel, Raffaele Fauvet, Pierre Emmanuel Colombo, Elsa Kalbacher, …

Journal of clinical oncology, Vol.32(15_suppl), pp.TPS5614-TPS5614

20/05/2014

DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.tps5614

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

Détails

Titre: A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable
Créateurs - sans rôle: Roman Rouzier - Institut Curie
Philippe Morice - Institut Gustave Roussy
Anne Floquet - Institut Bergonié
Frédéric Selle - Universite Pierre et Marie Curie, Oncology, GHU-Est Tenon, Paris, France
Eric Lambaudie - Institut Paoli-Calmettes
Virginie Fourchotte - Institut Curie
Christophe Pomel - Centre Jean Perrin
Raffaele Fauvet - CHU Amiens, Amiens, France
Pierre Emmanuel Colombo - Institut Regional du Cancer de Montpellier
Elsa Kalbacher - CHU Besançon, Besançon, France
Philippe Follana - Centre Antoine Lacassagne
Sandrine Martin - Centre François Baclesse, Caen, France
Anne Lesoin - Centre Oscar Lambret
Fabrice Lecuru - European Hospital George Pompidou, Paris, France
Patricia Pautier - Department of Medicine, Gustave Roussy, Villejuif, France
Frederic Guyon - Institut Bergonié
Paul H. Cottu - Institut Curie
Florence Joly - Comite Uro-Gynecologie, Centre François Baclesse, Caen, France
Youssef Ghazi - Roche, Boulogne-Billancourt, France
Elisabeth Chereau - Institut Paoli Calmette, Marseille, France
Détails de publication: Journal of clinical oncology, Vol.32(15_suppl), pp.TPS5614-TPS5614
Identifiants: 99140134509311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article